“Yellow card” announcement used to head off concerns, experts claimBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7410.308-a (Published 07 August 2003) Cite this as: BMJ 2003;327:308
- Lynn Eaton
Two leading experts in drug safety and efficacy claim that their calls for a major review of the United Kingdom's “yellow card” system for monitoring drug safety were headed off by a government announcement that an inquiry into the system was under way.
Andrew Herxheimer, emeritus fellow with the UK Cochrane Centre, and Charles Medawar, director of the consumer research group Social Audit, presented evidence to the Committee on Safety of Medicines in July. This followed a survey they had carried out for the BBC after its screening in October 2002 of a Panorama programme on the selective serotonin reuptake inhibitor paroxetine (Seroxat). The programme had highlighted concerns with the drug. A second Panorama programme in May 2003 …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial